
Lidocaine Raw Material Powder For Local Anesthetics CAS:137-58-6
Lidocaine raw material powder represents the fundamental, unformulated active pharmaceutical ingredient (API) that serves as the primary building block for a vast array of local anesthetic and antiarrhythmic medications. Unlike the final products found in clinics (solutions, gels, patches), the raw powder is the pure chemical entity before any processing into a patient-ready form. This detailed examination delves into the essence of this critical compound, exploring its characteristics, multifaceted applications, inherent benefits, and intricate pharmacokinetics from the unique perspective of its raw material state.
What is Lidocaine Raw Material Powder?
Lidocaine raw material powder is the purified, crystalline solid form of the chemical compound 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide. Its Chemical Abstracts Service (CAS) number is 137-58-6. As an API, it is manufactured and supplied under strict Good Manufacturing Practice (GMP) guidelines to ensure exceptional purity, often exceeding 99.5%. This powder is not intended for direct human or animal use; it is an industrial intermediate destined for pharmaceutical compounding. Its value lies in its versatility, serving as the core ingredient that pharmaceutical companies process into various formulations, including hydrochloride salts for injectable solutions, creams, ointments, sprays, and transdermal patches.

Distinctive Features of the Raw Material
The raw powder possesses specific physicochemical properties that define its handling, stability, and formulation potential:
●Physical Form: It typically appears as a white, odorless, crystalline powder. The crystal morphology can vary (polymorphism), which can influence its dissolution rate and stability, a critical factor for manufacturers.
●Lipophilicity: In its base form, lidocaine is poorly soluble in water but highly soluble in lipids (fats). This intrinsic property is paramount to its function, as it allows the molecule to readily diffuse through nerve cell membranes. For aqueous formulations like injections, it is converted to its water-soluble hydrochloride salt form (Lidocaine HCl).
●Stability: The powder is stable under recommended storage conditions-typically in a cool, dry, well-ventilated place, protected from light and moisture in tightly sealed containers. It is susceptible to degradation upon prolonged exposure to heat, light, or extreme pH levels.
●Melting Point: It has a defined melting point range (approximately 66-69°C for the base form), which is a key identifier and quality control parameter for raw material suppliers and recipients.
●Purity Profile: Rigorous analytical testing (HPLC, GC) confirms the absence of harmful impurities and residual solvents from the synthesis process, ensuring the safety and efficacy of the final drug product.
Applications: Beyond the Needle
While synonymous with injection, the raw material's adaptability allows for a wide spectrum of medical applications once formulated:
1.Injectable Anesthetics: The primary use. The powder is converted to Lidocaine Hydrochloride and dissolved in sterile water or saline to create solutions for infiltration anesthesia (direct injection into tissue), nerve blocks (targeting specific nerves), and epidural or spinal anesthesia.
2.Topical Formulations: Incorporated into creams, gels, lotions, and ointments (e.g., LMX 4%, EMLA® cream-a lidocaine-prilocaine mixture) for surface anesthesia on skin and mucous membranes before procedures, for treating sunburn pain, or for insect bites.
3.Mucosal Applications: Formulated into viscous solutions for oral, laryngeal, or nasal anesthesia to facilitate endoscopic procedures, intubation, or to suppress the gag reflex.
4.Ophthalmic Solutions: Used in eye drops for corneal anesthesia during tonometry or short surgical procedures.
5.Transdermal Patches: The powder is engineered into adhesive patches (e.g., Lidoderm®) designed to deliver the drug slowly through the skin for prolonged relief from neuropathic pain like post-herpetic neuralgia.
6.Antiarrhythmic Use: In its intravenous form, it is used in emergency medicine to treat life-threatening ventricular arrhythmias, leveraging its ability to block cardiac sodium channels.
Inherent Benefits and Advantages
The widespread adoption of lidocaine as the local anesthetic of choice for decades is due to a powerful combination of benefits rooted in its chemical structure:
●Rapid Onset of Action: Its moderate lipophilicity allows for swift diffusion into nerves, leading to a quick blockade of sodium channels and a fast onset of numbness.
●Predictable Duration: It provides an intermediate duration of action (typically 1-2 hours), which is ideal for a multitude of surgical and procedural applications. This can be prolonged with the addition of a vasoconstrictor like epinephrine.
●Proven Safety Profile: With decades of clinical use, its pharmacokinetics and toxicology are exceptionally well-understood, making it a reliable and trusted agent.
●Versatility: As evidenced by its applications, its chemical properties allow it to be formulated into almost any delivery system, making it indispensable across medical specialties.
●Cost-Effectiveness: The synthesis of lidocaine is well-established and efficient, making the raw material relatively inexpensive to produce, which translates to affordable end-products for healthcare systems.
Dosage: A Matter of Formulation and Application
Crucially, there is no single "dosage" for the raw material powder. It is a bulk ingredient. The dosage is determined during the pharmaceutical manufacturing process and is specific to the final product's concentration, formulation, and intended route of administration.
●Injectable Solutions: Commonly range from 0.5% to 2% concentration. Maximum recommended doses are strictly defined (e.g., 4.5 mg/kg without epinephrine, up to 7 mg/kg with epinephrine) to avoid systemic toxicity.
●Topical Creams/Gels: Typically range from 2% to 5%.
●Transdermal Patches: Contain a specific amount of drug per patch (e.g., 700 mg per patch for Lidoderm®, delivering ~10 mg/hour).
The role of the raw material manufacturer is to provide a consistent, pure powder so that pharmaceutical compounders can accurately and reliably achieve these precise dosages in their products.
Cycle: From Absorption to Elimination (Pharmacokinetics)
The "cycle" of lidocaine in the body refers to its pharmacokinetic journey, which begins once a formulated product is administered.
1.Absorption: The rate of absorption is highly dependent on the route of administration and vascularity of the site. Topical application leads to slow absorption, while injection into vascular tissue results in rapid entry into the bloodstream.
2.Distribution: Lidocaine is widely distributed throughout the body. It readily crosses the blood-brain and placental barriers. It has a moderate volume of distribution, meaning it is not confined solely to the bloodstream but distributes into tissues.
3.Metabolism: This is a critical step. Lidocaine undergoes extensive first-pass metabolism in the liver, primarily by the cytochrome P450 enzyme system (CYP1A2 and CYP3A4). It is metabolized into active metabolites like monoethylglycinexylidide (MEGX) and glycinexylidide (GX), which contribute to both efficacy and toxicity.
4.Elimination: The metabolites and a small fraction of unchanged drug are excreted via the kidneys into the urine.
Half-Life: The Measure of Duration
The elimination half-life of lidocaine-the time it takes for the plasma concentration to reduce by half-is approximately 1.5 to 2 hours in adults with normal hepatic and cardiac function. This parameter is crucial for understanding dosing intervals and potential drug accumulation. Several factors can dramatically alter its half-life:
●Liver Function: Hepatic impairment or reduced liver blood flow (e.g., from heart failure) can significantly prolong the half-life, increasing the risk of toxicity.
●Drug Interactions: Concomitant use of drugs that inhibit CYP3A4 enzymes (e.g., beta-blockers like propranolol, antifungals like ketoconazole) can slow metabolism and extend the half-life.
●Age: Neonates have immature liver enzymes, and the elderly may have reduced liver function, both leading to a prolonged half-life.
PTC: Professional and Technical Context
In the context of a raw material, PTC transcends "Pre-Trial Check" and is best interpreted as the Professional and Technical Context governing its lifecycle.
●Regulatory Compliance: The powder must meet stringent compendial standards (e.g., USP, Ph. Eur., JP) for identity, assay, purity, and impurities. This involves rigorous Certificate of Analysis (CoA) documentation.
●Supply Chain Integrity: Sourcing must be from approved, GMP-compliant suppliers to guarantee consistency, prevent contamination, and ensure traceability-a critical aspect of pharmaceutical quality assurance.
Clinical Data
|
Trade Names |
Lidocaine,Xylocaine, Ztlido,Lignocaine |
|
CAS |
137-58-6 |
|
Molar mass |
234.343 |
|
Formula |
C14H22N2O |
|
Purity |
Above 98% |
|
Apprarance |
White Crystalline Powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785

Conclusion
Lidocaine raw material powder is far more than a simple chemical; it is the foundational pillar upon which modern local anesthesia is built. Its unique physicochemical properties grant it unparalleled versatility, enabling its formulation into a diverse arsenal of medical products. Its well-characterized benefits, pharmacokinetics, and safety profile, underpinned by a robust professional and technical framework, cement its status as an irreplaceable tool in medicine. The journey from a bulk crystalline powder to a life-enhancing medical intervention is a testament to the sophistication of pharmaceutical science and the enduring value of this remarkable molecule.
Hot Tags: lidocaine raw material powder for local anesthetics cas:137-58-6, China lidocaine raw material powder for local anesthetics cas:137-58-6 manufacturers, suppliers, factory, Anastrozole, Anastrozole Treating and Preventing Female Breast Cancer, High purity API Methenolone Enanthate, Nolvadex to treat or prevent breast cancer, Sustanon, Trenbolone Acetate
